HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): W. Coosemans Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lerut, T. Articles by DeMeester, S. b. T. R. Search for Related Content PubMed PubMed Citation Articles by Lerut, T. Articles by DeMeester, S. b. T. R.

J Thorac Cardiovasc Surg 1994;107:1059-1066
© 1994 Mosby, Inc.

GENERAL THORACIC SURGERY

Surgical treatment of Barrett's carcinomaCorrelations between morphologic findings and prognosis

Leuven, Belgium

Sponsored by Tom R. DeMeester, MD

Los Angeles, Calif.

Address for reprints: T. Lerut, MD, PhD, Department of General Thoracic Surgery, U.Z. Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.

Abstract

Barrett's carcinoma occurred in 66 of 331 patients with adenocarcinomas of the esophagus or gastroesophageal junction. Only 32 (46%) of these patients had a history of gastroesophageal reflux. A history of alcohol and tobacco abuse was absent in 50% and 47.5%, respectively. The mean length of Barrett's metaplasia was 7.37 cm. Operability was 98.5% and resectability 95.5%. No postoperative or hospital deaths occurred. Pathologic staging was as follows: stage 0 and I, 38.3%; stage II, 20.6%; stage III, 22.2%; and stage IV, 19%. Overall survivals were 80.5% at 1 year, 62.7% at 2 years, and 58.2% at 5 years. Five-year survival for patients with stage I disease was 100%; for stage II, 87.5%; for stage III, 22.2%; and for stage IV, 0%. Thirty-four (51.5%) patients were under surveillance for a related or unrelated condition before diagnosis of their carcinoma; only nine (26.5%) had diseased lymph nodes. In 32 the diagnosis was made at their first medical contact, and 78% of them had diseased lymph nodes. Five-year survival without nodal metastasis was 85.3% and significantly better than for patients with metastasis, 38.3% (p = 0.0033). Of the 66 patients, 19 (28.7%) had a biopsy-proved history of Barrett's metaplasia before malignancy developed. Mean time interval between diagnosis of metaplasia and degeneration was 3.8 years (89.5% > 1 year). Over the surveillance period, the length of metaplastic Barrett's esophagus remained unchanged in all patients. Barrett's ulceration was present from the beginning in 14 patients, and three patients never had an ulcer. Intestinal metaplasia was seen in 18 patients. Resected specimens revealed severe dysplasia in 16 patients. Of the 19 patients, 73.7% had stage I disease. Our data suggest that close endoscopic monitoring and systematic biopsies of the smallest irregularities in the metaplastic mucosa may result in early detection of carcinoma. In this respect, patients with an ulcer within a zone of intestinal metaplasia seem to be at risk. Early detection increases substantially the chances for cure by diminishing the risks of lymph node involvement. Resection remains the treatment of choice in Barrett's adenocarcinoma including high-grade dysplasia, because mortality can be kept low with excellent to very good functional results in the majority of the patients provided the intervention is performed by experienced teams. (J THORAC CARDIOVASC SURG1994;107:1059-66)

This article has been cited by other articles:

				K. Oyama, T. Fujimura, I. Ninomiya, T. Miyashita, S. Kinami, S. Fushida, T. Ohta, and M. Koichi A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats Carcinogenesis, March 1, 2005; 26(3): 565 - 570. [Abstract] [Full Text] [PDF]

				R. E. Rudolph, T. L. Vaughan, A. R. Kristal, P. L. Blount, D. S. Levine, P. C. Galipeau, L. J. Prevo, C. A. Sanchez, P. S. Rabinovitch, and B. J. Reid Serum Selenium Levels in Relation to Markers of Neoplastic Progression Among Persons With Barrett's Esophagus J Natl Cancer Inst, May 21, 2003; 95(10): 750 - 757. [Abstract] [Full Text] [PDF]

				R. E. Rudolph, T. L. Vaughan, B. E. Storer, R. C. Haggitt, P. S. Rabinovitch, D. S. Levine, and B. J. Reid Effect of Segment Length on Risk for Neoplastic Progression in Patients with Barrett Esophagus Ann Intern Med, April 18, 2000; 132(8): 612 - 620. [Abstract] [Full Text] [PDF]

				T. Lerut, W. Coosemans, P. De Leyn, D. Van Raemdonck, G. Deneffe, and G. Decker Treatment of Esophageal Carcinoma* Chest, December 1, 1999; 116(suppl_3): 463S - 465S. [Abstract] [Full Text] [PDF]

				J W van Sandick, J J B van Lanschot, B W Kuiken, G N J Tytgat, G J A Offerhaus, and H Obertop Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma Gut, August 1, 1998; 43(2): 216 - 222. [Abstract] [Full Text] [PDF]

				S. J. Hoff, J. L. Sawyers, C. D. Blanke, H. Choy, and J. R. Stewart Prognosis of Adenocarcinoma Arising in Barrett's Esophagus Ann. Thorac. Surg., January 1, 1998; 65(1): 176 - 181. [Abstract] [Full Text] [PDF]

				C E Macdonald, A C Wicks, and R J Playford Ten years' experience of screening patients with Barrett's oesophagus in a university teaching hospital Gut, September 1, 1997; 41(3): 303 - 307. [Abstract] [Full Text] [PDF]

				A. G. Little Barrett's Esophagus Ann. Thorac. Surg., July 1, 1996; 62(1): 315 - 315. [Full Text]

				J. Johansson, F. Johnsson, B. Walther, R. Willen, C. S. von Holstein, and T. Zilling Adenocarcinoma in the Distal Esophagus With and Without Barrett Esophagus: Differences in Symptoms and Survival Rates Arch Surg, July 1, 1996; 131(7): 708 - 713. [Abstract] [PDF]